Stoke Therapeutics, Inc. (STOK): Free Cash Flow
$44.91M
Year ended 2025-12-31
-$180.68M
Trailing 12 months to 2026-06-30
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $44.91M | n/m | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | -$87.05M | n/m | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | -$82.68M | n/m | 2025-03-18, From 2023-01-01 |
| 2022-12-31 | -$35.83M | n/m | 2024-03-25, From 2022-01-01 |
| 2021-12-31 | -$68.11M | n/m | 2023-03-06, From 2021-01-01 |
| 2020-12-31 | -$43.27M | n/m | 2022-03-10, From 2020-01-01 |
| 2019-12-31 | -$32.69M | n/m | 2021-03-09, From 2019-01-01 |
| 2018-12-31 | -$11.90M | n/a | 2020-03-23, From 2018-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $44.91M | n/m |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | -$70.72M | n/m |
| Lifevantage Corp (LFVN) | 2026-06-30 | $6.67M | -36.5% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | -$116.63M | n/m |
| Cryoport, Inc. (CYRX) | 2025-12-31 | -$25.02M | n/m |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | -$167.00M | n/m |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | -$323.17M | n/m |
| Liquidia Corp (LQDA) | 2025-12-31 | -$40.02M | n/m |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | -$110.44M | n/m |
Compare STOK, MRVI, LFVN, RYTM side by side · Screen every company in Pharmaceutical Preparations ↗